Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Dominion Energy Inc (D) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Dominion Energy Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Dominion Energy Inc trades at $67.94 (market cap $59.06B). The key difference: Dominion Energy Inc is far larger — about 6.3× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Dominion Energy Inc pays a 3.98% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | D | |
|---|---|---|
Market Cap | $9.39B | $59.06B |
Sector | Health | Utilities |
52-Week High | $354.54 | $71.67 |
52-Week Low | $241.71 | $57.08 |
Enterprise Value | $9.14B | $113.18B |
Dividend Yield | — | 3.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
Dominion Energy (D) trades at $67.39, up 0.88% today, with a bearish technical signal but strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $0.79, exceeding expectations, and maintains a stable dividend. Revenue growth is robust, rising to $16.51B in 2025, with a net income margin of 13.99%. Analyst consensus is mixed, with a $70.43 price target, but technical indicators show resistance near $68.
Outlook remains cautious due to high debt levels and bearish technicals, though fundamentals are solid with consistent profitability. Risks include regulatory pressures and capital expenditure demands. The stock offers income appeal with dividends, but near-term price action may face headwinds from technical selling pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Dominion Energy Inc
Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion owns a liquefied natural gas export facility in Maryland and is constructing a 5.2 GW wind farm off the Virginia Beach coast.
Read more on D →
